Clinical trials: Papilloma Virus, Human
Anogenital Human Papilloma Virus Infection, Condyloma Acuminata
Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)
A study to evaluate the efficacy and tolerability of V501 (quadrivalent Human Papilloma Virus [HPV] [Type 6, 11, 16 and 18] L1 Virus-Like Particle vaccine, GARDASIL™) in healthy, 16- to 26-year old Japanese males.
- Trial name
- NCT01862874
- Testing
- V501
- Volunteers
- 1,124 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Papillomavirus
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females
The purpose of this study is to evaluate the immunogenicity and the safety of Cervarix administered according to a 2-dose schedule at 0, 6 months compared to Gardasil, administered according to a 2-dose schedule at 0, 6 months or…
- Trial name
- NCT01462357
- Testing
- Cervarix, Gardasil
- Where
- 21 sites in France, Hong Kong and 2 more
- Volunteers
- 1,079 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections, Papillomavirus Infections
Viral Load Determination and Biomarkers of High Risk Human Papillomavirus (HPV) - Types in HIV-positive Men
Human papillomavirus (HPV)-infection belongs to the most common sexually transmitted diseases worldwide. HIV-infected men having sex with men (MSM) are strongly associated with a higher prevalence of genital HPV-infection, a…
- Conditions
- HIV Infections, Papillomavirus Infections, Anal Intraepithelial Neoplasia
- Trial name
- NCT00365729
- Testing
- Smear and biopsy testing for HPV-types and viral load
- Where
- 2 sites in Germany
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Deutsche Luft und Raumfahrt
Papillomavirus Infections
Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.
The purpose of this study was to evaluate efficacy of 851B gel over a range of concentrations and dosing regimens on high-risk cervical human papillomavirus infection in women.
- Trial name
- NCT00312286
- Testing
- 851B
- Where
- 93 sites in United States, Canada and 1 more
- Volunteers
- 538 people
- Sponsor
- Takeda
HPV Genital Infection (Primary Condition Studied), Bacterial Vaginosis
Kinetics and Ecology of Human Papillomavirus Genital Infections in Young Women
Most genital infections by human papillomaviruses (HPV) are asymptomatic or benign and clear within a few months or years. There infections are much less studies than chronic infections, even though they represent the main…
- Conditions
- HPV Genital Infection (Primary Condition Studied), Bacterial Vaginosis, Chlamydiae Infection
- Trial name
- PAPCLEAR (NCT02946346)
- Testing
- vaginal sampling
- Where
- France
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Atypical Endometrial Hyperplasia, Human Papillomavirus Infection
CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells
This research trial studies carbonic anhydrase 9 (CA-IX), p16, proliferative markers, and human papilloma virus (HPV) in diagnosing cervical lesions in patients with abnormal cervical cells.
- Conditions
- Atypical Endometrial Hyperplasia, Human Papillomavirus Infection, Stage 0 Cervical Cancer AJCC v7
- Trial name
- NCT00892866
- Testing
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Where
- 163 sites in United States, Japan and 1 more
- Volunteers
- 877 people
- Sponsor
- GOG Foundation
Uterine Cervical Cancer
Evaluation of First-void Urine as an Alternative to Cervical Sampling for Human Papillomavirus (HPV) Testing in Cervical Cancer Screening (Single-center Study).
Papillomaviruses are responsible for almost all cervical cancers. In France, there are more than 3000 new cases of cervical cancer each year and nearly 1000 deaths.
- Trial name
- URAPREV (NCT06254846)
- Testing
- Urine sample, 1st stream, Cervico-vaginal swab
- Where
- France
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Research Human Papillomavirus ( HPV) by Vaginal Auto-takings ( APV) and Urinary Test
Research for Papillomavirus as the Examination of Orientation in the Organized Screening of the Cervical Cancer
Auto-takings by APU and vaginal APV during the consultations for FCU in the department of gynecology-obstetrics (Group 1) according to an instructions for use proposed to the inclusive women, with consent; the same proposal, APU…
- Trial name
- PapU-APV (NCT02137694)
- Testing
- vaginal auto-takings and urinary test
- Where
- 2 sites in France
- Volunteers
- 460 people
- Sponsor
- University Hospital, Brest
Hiv Infection
Human Papillomavirus Infection and Related Anal Lesions in HIV-positive Men Who Have Sex With Men
Multicentric epidemiological non-comparative study in France characterising evolution of anal Human papillomavirus (HPV) infection and related lesions and evaluating markers associated with the observed evolution.
- Trial name
- APACHES (NCT02287961)
- Testing
- Standard proctologic examination, High resolution anoscopy, Biopsy(ies) during High Resolution Anoscopy
- Where
- France
- Volunteers
- 516 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Human Papillomavirus Infection, Human Papillomavirus-Related Malignant Neoplasm
Extended Follow-up of Women Who Received One, Two, and Three Doses of the HPV Vaccine in the Costa Rica Vaccine Trial (CVT), ESCUDDO-CVT Study
This study is extending follow up of women who participated in the Costa Rica Vaccine Trial (CVT) and received one dose or two doses of the human papillomavirus (HPV) vaccine, along with a group of women who received three doses.
- Trial name
- NCT03309033
- Testing
- Biospecimen Collection, Questionnaire Administration
- Where
- Costa Rica
- Volunteers
- 946 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer
Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer
RATIONALE: Vaccines made from human papillomavirus may make the body build an immune response to and kill cervical cancer cells. Combining vaccine therapy with surgery may be a more effective treatment for cervical cancer.
- Trial name
- NCT00002916
- Testing
- human papillomavirus 16 E7 peptide, synthetic human papillomavirus 16 E6 peptide, adjuvant therapy
- Where
- 10 sites in Austria, France and 5 more
- Volunteers
- 44 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
HPV, Human Papillomavirus Viruses, Human Papilloma Virus Vaccine
SMS Reminders to Strengthen Demand for HPV Vaccination in Georgia
It is possible that achieving adequate HPV vaccination coverage will allow cervical cancer to be virtually eliminated. This is a priority for Georgia, where the burden of mortality and morbidity from cervical cancer is high and…
- Trial name
- NCT05536674
- Testing
- SMS reminder for the HPV vaccination
- Volunteers
- 55,176 people, healthy volunteers welcome
- Sponsor
- The Behavioural Insights Team
HPV InfectioN, HPV-Related Carcinoma
A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 18-45 Years
A total of 13500 Chinese women aged 18-45 years old were divided into three age groups: 18-26 years old, 27-35 years old, and 35-45 years old. The experimental group and the placebo group were randomly assigned in a ratio of 1:1.
- Trial name
- NCT05262010
- Testing
- 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
- Where
- 8 sites in China
- Volunteers
- 13,500 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Effects of Immunotherapy, Metastatic/Recurrent Cervical Cancer
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
To evaluate the tolerability and safety of axalimogene filolisbac 1 x 10^10 colony forming units (cfu) administered with prophylactic premedication in repeating 3-dose study cycles in women with persistent, metastatic, or…
- Conditions
- Effects of Immunotherapy, Metastatic/Recurrent Cervical Cancer, Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma
- Trial name
- NCT02164461
- Testing
- Axalimogene filolisbac
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Advaxis, Inc.
Human Papilloma Virus
Efficacy of an Intravaginal Treatment With Carboxymethyl-β-glucan and Polycarbophil in HR-HPV Clearance
These treatments are beta-glucans, polysaccharides of beta-D-glucose that, can influence the clearance of HPV infection. The objective of this study is to evaluate the efficacy of a gel with Carboxymethyl - β -Glucan and…
- Trial name
- GLUCANVIR (NCT04781023)
- Testing
- Colpofix
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Uriach Consumer Healthcare
Cervical Intraepithelial Neoplasia, Cervical Cancer
HPV Integration Testing for Human Papillomavirus-Positive Women
Papanicolaou (Pap) triage, with high specificity, has been recommended for primary Human papillomavirus (HPV) testing but is flawed by poor sensitivity and cytologist dependence.
- Trial name
- NCT02576262
- Testing
- TCT，HPV，colposcopic inspection
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Huazhong University of Science and Technology
Human Papilloma Virus, Cervical Cancer
The Selfie Study- Assessing Novel Markers for Cervical Cancer Screening From Self-collected Samples
Cervical cancer is primarily caused by Human Papillomaviruses (HPV). Testing for HPV in cervical samples is now an option for cervical cancer screening.
- Conditions
- Human Papilloma Virus, Cervical Cancer, CIN 2/3
- Trial name
- SELFIE (NCT04423679)
- Testing
- Evalyn Brush
- Where
- United States
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- George Washington University
Human Papilloma Virus, Human Immunodeficiency Virus
Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV
The goal of this study is to test the maximum tolerated dose of ACU-D1 in HIV-positive people with HPV-associated vulvar and perianal lesions.
- Conditions
- Human Papilloma Virus, Human Immunodeficiency Virus, Anal Intraepithelial Neoplasia, High-Grade Squamous Intraepithelial Lesions
- Trial name
- NCT06233331
- Testing
- Dose Level 1 ACU-D1 ointment, Dose Level 2 ACU-D1 ointment, Dose Level 3 ACU-D1 ointment
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Emory University
Vaccine Refusal
An Online Intervention Promoting HPV Vaccination Among Chinese MSM
Hong Kong Chinese speaking men who have sex with men completed a baseline survey, and then received an online intervention promoting uptake of Human Papillomavirus (HPV) vaccination.
- Trial name
- NCT04815837
- Testing
- Intervention
- Where
- Hong Kong
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Cervical Cancer, Condylomata Acuminata
Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women
This study is designed to compare plateau antibody levels of a novel recombinant human papillomavirus vaccine (types 6,11,16,18,31,33,45,52,58 )(E.Coli) manufactured by Xiamen Innovax Biotech CO., Ltd., with Gardasil®9 in females…
- Trial name
- NCT06197802
- Testing
- Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli), Gardasil®9
- Where
- China
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Xiamen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.